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Abstract: Objective: To investigate the levels of serum cystatin C (CysC) and chemokine (Chemerin) in patients with 
diabetic retinopathy (DR) and their roles in the onset and progression of DR. Methods: A total of 150 diabetic pa-
tients were enrolled as subjects and randomly divided into three groups: the proliferative DR (PDR) group (n=50), 
the non-proliferative DR (NPDR) group (n=50) and the control group (diabetes mellitus (DM) alone, n=50). In addi-
tion, 50 healthy adults were selected as normal controls. The four groups of patients were compared in demograph-
ic characteristics and biomarkers including gender, age, body mass index (BMI), glycosylated hemoglobin (HbA1c), 
homeostasis model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), triglyceride (TG), 
total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high sensitive C reactive protein (hsCRP), as well 
as serum cystatin C and Chemerin levels. Besides, Pearson correlation analysis and Logistics regression analysis 
were performed. Results: The control group was associated with a significant increase in serum CysC and Chemerin 
levels as compared with the normal control group; the patients with PDR or NPDR showed significantly higher levels 
than those with diabetes mellitus (DM) alone; and the ones with PDR had significantly higher levels than those 
with NPDR. The serum CysC and Chemerin levels were significantly different across groups and increased with the 
severity of the disease (P<0.05). Pearson correlation analysis showed that the serum CysC levels were positively 
associated with systolic blood pressure (SBP), HbA1c, HOMA-IR, FPG, TG, TC and LDL-C (P<0.05), and the serum 
Chemerin levels were positively associated with BMI, HOMA-IR, urinary albumin and hsCRP (P<0.05). What’s more, 
the serum CysC levels were also positively associated with the serum Chemerin levels (P<0.05). Multivariate logistic 
regression analysis indicated that serums CysC and Chemerin were independent risk factors for DR. Conclusion: 
Elevated serum CysC and Chemerin levels are risk factors for DR, and they play a role in the pathogenesis of DR. 
Thus they are likely to become potential markers for assessment of DR.
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Introduction
Diabetic retinopathy (DR), one of the most com-
mon complications of diabetes mellitus (DM), is 
of clinical significance to improve prevention 
and treatment of the disease and reduce the 
incidence of blindness in patients with DM. It is 
well-known that DR and diabetic nephropathy 
belong to hyperglycemia-induced microvascu-
lar diseases. Early diagnosis and treatment of 
DR is the key to prevention and the treatment 
of this disease. There are no effective biologi-
cal parameters for assessment of DR. Cystatin 
C (CysC) is a low molecular-weight, non-glyco-
sylated basic protein belonging to the cystatin 
super-family of cysteine proteinase inhibitors. 
Its main role is to suppress the activity of 
endogenous cysteine protease. CysC, as a met-
abolic intermediate of methionine, is closely 
related to the onset of diabetic nephropathy. It 
is extensively used to assess glomerular filtra-
tion, which has been confirmed in the studies 
[1]. However, the studies on the association 
between CysC and diabetic microangiopathy 
are limited to diabetic nephropathy, and few 
studies are involved in the effect of CysC on the 
progression of DR. In addition, both national 
and international studies show that retinal 
inflammation is characteristic of DR. Chemerin 
as a fat cell factor is involved in the immuno-
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lesion response by binding to many inflamma-
tory cytokines [2, 3]. In recent years, studies 
have demonstrated that elevated serum 
Chemerin levels lead to insulin resistance and 
are involved in the pathogenesis of diabetic 
microangiopathy [4]. However, whether it is 
related to DR remains controversial, and there 
are few reports about it. The present study was 
designed to analyze the serum CysC and 
Chemerin levels in patients with DR, and to 
investigate the relationship between CysC, 
Chemerin and DR.
Materials and methods
Demographic characteristics
A total of 150 patients with DM treated in our 
hospital from January 2014 to December 2016 
were enrolled as the subjects in this retrospec-
tive study. All the patients met the diagnosis 
criteria listed in China Guidelines for Type 2 
Diabetes (Version 2010), and met the require-
ments in this study. According to the Diabetic 
Retinopathy Staging Criteria created by the 
Ocular Fundus Disease Branch of Chinese 
Medical Association in 1984 and the results of 
ophthalmoscopy and fluorescein fundus angi-
ography, the subjects were divided into three 
groups: 50 were in the proliferative diabeticret-
inopathy (PDR) group, whose ocular fundi 
showed neovascularization, vitreous hemor-
rhage or pre-retinal hemorrhage; 50 were in the 
non-proliferative DR (NPDR) group whose ocu-
lar fundi showed microaneurysms, more than 
20 events of intra-retinal hemorrhage in any 
quadrant, vein beaded changes in more than 
two quadrants or significant intra-retinal micro-
vascular abnormalities in more than one quad-
rant; 50 were in the control group whose ocular 
fundi showed no abnormalities. Any patient 
presented any one of the following conditions 
was excluded: autoimmune diseases, connec-
tive tissue diseases, cerebrovascular diseases, 
liver and kidney dysfunction, malignant tumor, 
acute and chronic infections, diabetes and 
chronic complications, pregnancy and ocular 
diseases for any other causes, or recently treat-
ed with large doses of hormone agents or eye 
surgery. In addition, 50 healthy adults were 
selected in the normal control group. All the 
healthy subjects had no hypertension, coronary 
heart disease, diabetes or any other disease 
history affected the results of the study. This 
study was in accordance with the medical eth-
ics principles of the hospital, and qualified in 
the ethical reviews. All participants signed the 
informed written consents.
Study methods
Ophthalmoscopy
Direct ophthalmoscope was used to check first 
the macula regions and the posterior pole, and 
then the peripheral parts in order from the 
nasal, superior, temporal to lower retina.
Fluorescein fundus angiography
Fluorescein sodium injection (3 mL) was inject-
ed into the ulnar vein of each subject. Ten sec-
onds after injection, 10 photographs of the 
posterior pole were successively shot with a 
Fule450-type digital retinal camera, followed 
by orderly shooting at the nine sites including 
posterior pole, temporal, nasal, superior, and 
lower, above and below the nose, above and 
below the temple at 1, 3, 5, and 10 minutes 
respectively. Finally at 20 minutes, the needed 
photographs were processed using the com-
puter image processing software.
Determination of CysC and Chemerin
The venous blood sample (5 mL) was collected 
from each fasting subject in the early morning. 
After 30 minutes without shaking, the samples 
were centrifuged, from which serum was sepa-
rated and cryopreserved for detection. With the 
use of enzyme linked immunosorbent assay 
(ELISA), serum CysC and Chemerin levels were 
detected in strict accordance with the instruc-
tions of the human CysC and Chemerin kits 
(Shanghai Vinhaket Biological Technology Co. 
Ltd). Serum CysC and Chemerin levels were 
compared among subjects from the four 
groups.
Monitoring parameters
The patients’ general data on sex, age, body 
mass index (BMI), duration of disease, systolic 
blood pressure (SBP) and diastolic blood pres-
sure (DBP) were recorded. The Backman AU680 
automatic biochemical analyzer was used to 
measure glycosylated hemoglobin (HbA1c), 
fasting plasma glucose (FPG), triglyceride (TG), 
total cholesterol (TC), low density lipoprotein 
cholesterol (LDL-C), high density lipoprotein 
cholesterol (HDL-C), urinary albumin, hypersen-
sitivity C reactive protein (hsCRP); HOMA-IR 
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=FPG * fasting insulin/22.5. The factor includ-
ing general information, clinical and biomarkers 
including gender, age, BMI, duration of disease, 
SBP, DBP, HbA1c, HOMA-IR, FPG, TG, TC, LDL-C, 
HDL-C, urinary albumin and hsCRP were com-
pared among the subjects in the 4 groups.
Statistical analysis
The data analysis in the study was performed 
using SPSS software, version 12.0. The mea-
surement data with normal distribution were 
presented as mean ± S.D, and the inter-group 
differences were compared using univariate 
analysis of variance (ANOVA). The qualitative 
data were expressed as percentages, and the 
inter-group differences were compared using 
the chi-square test. The associations of serum 
CysC and Chemerin levels with all other param-
eters were assessed with the use of Pearson 
correlation analysis. Multivariate logistic re- 
gression analysis was applied to determine 
independent risk factors for DR.
Results
Demographic characteristics of patients 
across groups
There were no significant differences in gender 
and age among the patients across groups. 
BMI and systolic blood pressure were signifi-
cantly different when the PDR group, the NPDR 
group and the diabetes control group were 
compared with the normal control group, 
respectively. The patients with PDR had signifi-
cantly higher SBP values than those with 
DMalone (P<0.05), and also had significantly 
higher DBP values than those of normal con-
trols (P<0.05; Table 1).
Comparison of biomarkers across groups
There were significantly reductions in HOMA-IR, 
urinary albumin and hsCRP levels among the 
patients in the PDR group, the NPDR group, the 
control group and the normal control group 
(P<0.05). Compared with the normal control 
group, the levels of HbA1c, FPG, TG, TC, LDL-C 
improved significantly among the patients in 
the PDR group, the NPDR group and the control 
group (P<0.05). The HbA1c, TC and FPG levels 
were significantly higher in the PDR group than 
in the control group (P<0.05; Table 2).
Serum cystatin C levels in all groups
The serum CysC levels of the patients with 
DMalone (0.68±0.04 mg/L) were significantly 
higher than those of the normal controls 
(0.32±0.02 mg/L) but markedly lower than the 
Table 1. Demographic characteristics of patients across groups
Groups Gender (Male/Female) (n) Age (years) BMI (kg/m2) SBP (mmHg) DBP (mmHg)
PDR 27/23 48.9±7.2 26.4±2.46* 139.56±14.71*,# 79.31±10.21*
NPDR 26/24 47.8±7.7 25.6±2.51* 135.72±15.32* 75.72±9.82
Control 28/22 49.1±6.9 25.2±2.44* 130.11±10.64* 75.54±8.91
Normal control 25/25 50.1±6.7 21.6±1.96 121.15±9.67 73.20±4.76
Note: *P<0.05 for the comparison with the normal control group; #P<0.05 for the comparison with the diabetes control group.
Table 2. Comparison of biomarkers across groups
Parameters PDR NPDR Controls Normal controls
HbA1c (%) 9.96±2.55*,# 9.58±2.21* 9.22±2.11* 4.42±0.32
HOMA-IR 7.92±2.31*,#,Δ 6.85±2.26*,# 5.97±1.94* 1.69±0.26
FPG (mmol/L) 9.62±3.44*,# 9.31±2.83* 7.64±4.16* 4.79±0.79
TG (mmol/L) 2.40±1.94* 2.25±2.45* 2.04±1.31* 1.19±0.28
TC (mmol/L) 5.70±1.22*,# 5.58±0.91* 5.34±0.94* 4.42±0.66
LDL-C (mmol/L) 3.35±0.86* 3.05±0.69* 3.11±0.77* 2.65±0.49
HDL-C (mmol/L) 1.30±0.41 1.20±0.40 1.16±0.37 1.23±0.32
Urinary albumin (mg/24 h) 359±91.21*,#,Δ 50±11.92*,# 23±6.32* 3±2.24
hsCRP (mg/L) 1.83±0.58*,#,Δ 1.25±0.23*,# 0.78±0.16* 0.14±0.06
Note: *P<0.05 for the comparison with the normal control group; #P<0.05 for the comparison with the control group; ΔP<0.05 
for the comparison with the NPDP group.
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patients with NPDR (0.98±0.05 mg/L) and 
those with PDR (1.46±0.06 mg/L). Moreover, 
the serum CysC levels were significantly higher 
in the patients with PDR than in those with 
NPDR (P<0.05), on an escalating increase with 
the severity of disease (Figure 1).
Analysis on serum Chemerin levels among the 
patients in each group
There was a gradual decrease in serum 
Chemerin among the patients with PDR 
(43.21±7.12 ng/mL), with NPDR (37.25±6.8 
ng/mL), with DMalone (30.04±6.53 ng/mL), 
and normal controls (11.65±8.41 ng/mL), 
respectively. The inter-group difference in 
serum Chemerin level was statistically signifi-
cant (P<0.05; Figure 2).
Analyses on the correlations of serum CysC 
and Chemerin levels to other parameters
Pearson correlation analysis showed that the 
serum CysC levels were positively associated 
with SBP, HbA1c, HOMA-IR, FPG, TG, TC and 
LDL-C (r shows 0.515, 0.365, 0.278, 0.424, 
0.586, 0.639, 0.470, respectively, P<0.05; 
Table 3). The serum Chemerin levels were posi-
tively associated with BMI, HOMA-IR, urinary 
albumin and hsCRP (r shows 0.314, 0.238, 
0.648, 0.421, respectively, P<0.05). What’s 
more, CysC levels were also positively correlat-
ed with Chemerin levels (r shows 0.863, 
P=0.002; Table 4).
Multivariate logistic regression analysis
Multivariate logistic regression analysis, taken 
with or without DR as dependent variables and 
gender, age, BMI, blood pressure, HbA1c, FPG, 
TG, TC, LDL-C, HDL-C, HOMA-IR, urinary albu-
min, hsCRP, serums CysC and Chemerin as 
independent variables, showed that CysC, 
Figure 1. Comparison of expression levels of serum 
CysC among the patients in all the groups. *P<0.05 
for the comparison with the normal control group; 
#P<0.05 for the comparison with the control group; 
ΔP<0.05 for the comparison with the NPDR group.
Figure 2. Comparison of expression levels of se-
rum Chemerin among the patients in all the groups. 
*P<0.05 for the comparison with the normal control 
group; #P<0.05 for the comparison with the control 
group; ΔP<0.05 for the comparison with the NPDR 
group.
Table 3. Correlations of serum CysC levels 
and other parameters
CysC
r value P value
SBP 0.515 0.008
HbA1c 0.365 0.016
HOMA-IR 0.278 0.021
FPG 0.424 0.011
TG 0.586 0.006
TC 0.639 0.004
LDL-C 0.470 0.009
Table 4. Correlations of serum Chemerin 
levels and other parameters
Chemerin
r value P value
BMI 0.314 0.014
HOMA-IR 0.238 0.018
Urinary albumin 0.648 0.005
hsCRP 0.421 0.012
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Chemerin, LDL-C and HbA1c were risk factors 
for DR, and CysC and Chemerin were indepen-
dent risk factors for DR (Table 5).
Discussion
Chronic inflammation plays a crucial role in the 
onset and progression of diabetic complica-
tions. One study found that retinal inflamma-
tion is decisive for the pathogenesis of DR. 
Inflammatory factors adiponectin and TNF- 
alpha made changes in the patient’s aqueous 
humor adiponectin and serum levels and inter-
act with each other, thereby affecting progres-
sion of DR [5]. Therefore, it is of value to assess 
the severity and prognosis of DR by figuring out 
specific biological parameters of DR.
CysC is an ideal parameter for glomerular filtra-
tion rate [6]. The kidney and micro-vessels of 
Type 2 diabetic patients have been reported to 
express serum CysC [7]. Another study report-
ed that CysC increases the permeability of reti-
nal blood vessels and stimulates the growth of 
intraocular neovascularization [8]. It enhances 
the inflammatory response of the retina, lead-
ing to immunolesions. Serum CysC also reduc-
es the consumption of glucose, further increas-
es the intensity of insulin resistance and 
worsens prognosis [9, 10]. These results sug-
gest that CysC is a risk factor for DR. In the 
present study, serum CysC was detected in 
patients with PDR, NPDR or diabetic mellitus 
alone as well as healthy controls. The results 
showed that the serum CysC levels of the 
patients with diabetes alone were significantly 
higher than those of the normal controls but 
markedly lower than the patients with NPDR 
and those with PDR. Moreover, the serum CysC 
levels were significantly higher in patients with 
PDR than in those with NPDR, on an escalating 
increase with the severity of disease. The inter-
group difference in serum CysC levels was sig-
nificant. Multivariate logistics regression analy-
emia and hypoxia, and ultimately to the pres-
ence of lesions. As an inflammatory mediator, 
serum CysC makes direct damages to the 
microvascular functions and structure. Another 
study showed that serum CysC promotes 
inflammatory response, and high glucose-
induced microvascular inflammatory injury is 
the pathogenesis of DR, which further implies 
that serum CysC is closely related to diabetic 
microangiopathy [11].
Chemokin as a fat cell factor is involved in the 
inflammatory response of the body [12-14]. It 
has been found that Chemerin also mediates 
angiogenesis, which plays an essential role in 
the onset and progression of DR [15]. Chemerin 
inhibitor has been found to reduce the levels of 
serum CysC, tumor necrosis factor alpha and 
C-reactive protein, which is conducive to elimi-
nation of inflammatory reaction [16]. This sug-
gests that high glucose-induced Chemerin 
release not only makes direct damages to 
micro-vessels of retina in diabetic mellitus 
leading to DR, but also enhances inflammatory 
response and aggravates inflammatory dam-
ages to DR. The results of the present study 
showed that the serum Chemerin levels 
increased with the aggravation of DR. Pearson 
correlation analysis showed that serum Ch- 
emerin levels were positively associated with 
CysC levels, and Chemerin is one of the inde-
pendent risk factors for DR. In addition, epide-
miological studies show that serum Chemerin 
levels were higher in patients with type 2 diabe-
tes than in those of healthy controls. With 
effective hypoglycemic treatment, there was a 
reduction in the serum Chemerin levels and in 
the intensity of insulin resistance. This further 
shows that the serum Chemerin levels interact 
with HOMA-IR [17, 18].
Besides, the Pearson correlation analyses on 
serum CysC and Chemerin levels, demographic 
characteristics and various parameters showed 
Table 5. Multivariate logistic regression analysis on risk 
factors for DR
Variables Regression 
coefficients
SE OR 95% CI P value
CysC 2.125 0.854 8.461 1.603-40.408 0.013
Chemerin 1.524 0.689 4.949 1.203-17.938 0.024
HbA1c 1.968 0.928 4.389 1.139-43.687 0.033
LDL-C 1.517 0.678 4.591 1.168-17.956 0.026
sis also showed that serum CysC was 
one of the independent risk factors for 
DR, indicating that serum CysC, to 
some degree, affects the onset and 
progression of DR. The reasons may 
be that serum CysC improves the pro-
liferation of smooth muscle cells in 
micro-vessels of the retina of patients 
with DR, leading to microvascular 
occlusion which causes retinal isch-
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that serum CysC and Chemerin levels were pos-
itively associated with HOMA-IR, which fully 
indicates that the positive correlations of serum 
CysC and Chemerinin levels to insulin resis-
tance in patients with type 2 diabetes aggra-
vate dysglycemia. National and international 
scholars hold that Chemerin promotes the 
release of inflammatory factors, such as tumor 
necrosis factor alpha, C- reactive protein etc. 
[19-21]. This suggests that Chemerin may be 
concomitantly implicated in the pathogenesis 
of both type 2 diabetes mellitus and insulin 
resistance. The findings of the present study 
showed that the serum CysC levels were posi-
tively associated with HbA1c, HOMA-IR, FPG, 
TG, TC and LDL-C (P<0.05); and the serum 
Chemerin levels were positively related to BMI, 
HOMA-IR, urinary albumin and hsCRP (P<0.05). 
What’s more, the serum CysC levels were also 
positively associated with the serum Chemerin 
levels (P<0.05). This shows that in the onset 
and progression of DR, elevated CysC and 
Chemerin levels lead to disorders of lipid 
metabolism, dysglycemia, and intense insulin 
resistance, resulting in abnormal microcircula-
tion, and ultimately in such lesions as retinal 
ischemia and hypoxia and neovascularization. 
This further indicates that changes in serum 
CysC and Chemerin levels are closely related to 
the onset and progression of DR, and of signifi-
cance to the inflammatory response in DR.
Due to the small sample size and single-center 
in nature, there are still some limitations and 
selection of bias in the present study. Addition- 
al multi-centered, large-sampled, randomized 
controlled studies are required to further 
improve the research.
In conclusion, significant increases in serum 
CysC and Chemerin levels were observed in 
patients with DR. The serum CysC and Chemerin 
levels are not only implicated in the onset and 
progression of DR, but also to a certain extent 
express the severity of damages to retinopathy 
in diabetic patients. It indicates that elevated 
serum CysC and Chemerin levels are risk fac-
tors for DR and likely to become a marker for 
DR.
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